• 1
    Auersperg N, Edelson M, Mok S, Johnson S, Hamilton T. The biology of ovarian cancer. Sem Oncol 1998; 25: 281304.
  • 2
    Kohno T, Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 1999; 20: 140310.
  • 3
    Herman J. p16(INK4): involvement early and often in gastrointestinal malignancies. Gastroenterology 1999; 116: 4835.
  • 4
    Esteller M, Corn P, Baylin S, Herman J. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 32259.
  • 5
    Hahn S, Schutte M, Hoque A, Moskaluk C, da Costa L, Rozenblum E, Weinstein C, Fischer A, Yeo C, Hruban R, Kern S. DPC4, a candidate tumor suppressor gene at human chromosome 18q211. Science 1996; 271: 3503.
  • 6
    Kamb A, Gruis N, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian S, Stockert E, Day R III, Johnson B, Skolnick M. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 43640.
  • 7
    Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner S, Giovanella BC, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and protate cancer. Science 1997; 275: 19437.
  • 8
    Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 78992.
  • 9
    Ross D, Scherf U, Eisen M, Perou C, Rees C, Spellman P, Iyer V, Jeffrey S, Van de Rijn M, Waltham M, Pergamenschikov A, Lee J, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000; 24: 22735.
  • 10
    Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer Cancer 1997; 79: 595604.
  • 11
    Wu W, Kemp B, Proctor M, Gazdar A, Minna J, Hong W, Mao L. Expression of DMBT1, a candidate tumor suppressor gene, is frequently lost in lung cancer. Cancer Res 1999; 59: 184651.
  • 12
    Rosenberg M, Hui L, Ma J, Nusbaum H, Clark K, Robinson L, Dziadzio L, Swain P, Keith T, Hudson T, Biesecker L, Flint J. Characterization of short tandem repeats from thirty-one human telomeres. Genome Res 1997; 7: 91723.
  • 13
    Knight S, Lese C, Precht K, Kuc J, Ning Y, Lucas S, Regan R, Brenan M, Nicod A, Lawrie N, Cardy D, Nguyen H, et al. An optimized set of human telomere clones for studying telomere integrity and architecture. Am J Hum Genet 2000; 67: 32032.
  • 14
    Pineau P, Nagai H, Prigent S, Wei Y, Gyapay G, Weissenbach J, Tiollais P, Buendia M, Dejean A. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene 1999; 18: 312734.
  • 15
    Hecker KH, Roux KH. High and low annealing temperatures increase both specificity and yield in touchdown and stepdown PCR. Biotechniques 1996; 20: 47885.
  • 16
    Chang S, Khoo C, DePinho R. Modeling chromosomal instability and epithelial carcinogenesis in the telomerase-deficient mouse. Semin Cancer Biol 2001; 11: 22739.
  • 17
    Marchio A, Mehdeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, Dejean A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chrom Cancer 1997; 18: 5965.
  • 18
    Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997; 14: 292733.
  • 19
    Jones M, Melan M, Witt-Enderby P. Melatonin decreases cell proliferation and transformation in a melatonin receptor-dependent manner. Cancer Lett 2000; 151: 13343.
  • 20
    Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E, Richards R. Chromosomal fragile site FRA16D and DNA instability in cancer. Cancer Res 2000; 60: 16839.
  • 21
    Huebner K, Garrison P, Barnes L, Croce C. The role of the FHIT/FRA3B locus in cancer. Annu Rev Genet 1998; 32: 731.
  • 22
    Paige A, Taylor K, Taylor C, Hillier S, Farrington S, Scott D, Porteous D, Smyth J, Gabra H, Watson J. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 2001; 98: 1141722.
  • 23
    Liu C, Musco S, Lisitsina N, Forgacs E, Minna J, Lisitsyn N. LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res 2000; 60: 19617.
  • 24
    Steck P, Pershouse M, Jasser S, Yung W, Lin H, Ligon A, Langford L, Baumgard M, Hattier T, Davis T, Frye C, Hu R, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q233 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 35662.
  • 25
    Vlietstra R, van Alewijk D, Hermans K, van Steenbrugge G, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 27203.
  • 26
    Gusella J, Ramesh V, MacCollin M, Jacoby L. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1999; 1423: M29M36.
  • 27
    Goutebroze L, Brault E, Muchardt C, Camonis J, Thomas G. Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol 2000; 20: 1699712.
  • 28
    Englefield P, Foulkes W, Campbell I. Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12. Br J Cancer 1994; 70: 9057.
  • 29
    Sekido Y, Pass H, Bader S, Mew D, Christman M, Gazdar A, Minna J. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 122731.
  • 30
    Reiss M, Santoro V, de Jonge R, Vellucci V. Transfer of chromosome 18 into human head and neck squamous carcinoma cells: evidence for tumor suppression by Smad4/DPC4. Cell Growth Differ 1997; 8: 40715.
  • 31
    Shew J, Lin B, Chen P, Tseng B, Yang-Feng T, Lee W. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc Natl Acad Sci USA 1990; 87: 610.
  • 32
    Watanabe Y, Haugen-Strano A, Umar A, Yamada K, Hemmi H, Kikuchi Y, Takano S, Shibata Y, Barrett J, Kunkel T, Koi M. Complementation of an hMSH2 defect in human colorectal carcinoma cells by human chromosome 2 transfer. Mol Carcinog 2000; 29: 3749.
  • 33
    Karuman P, Gozani O, Odze R, Zhou X, Zhu H, Shaw R, Brien T, Bozzuto C, Ooi D, Cantley L, Yuan J. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001; 7: 130719.
  • 34
    Jenne D, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Muller O, Back W, Zimmer M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18: 3843.
  • 35
    MacLeod R, Dirks W, Matsuo Y, Kaufmann M, Milch H, Drexler H. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 1999; 83: 55563.
  • 36
    Masters J, Thomson J, Daly-Burns B, Reid Y, Dirks W, Packer P, Toji L, Ohno T, Tanabe H, Arlett C, Kelland L, Harrison M, et al. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 2001; 98: 80127.
  • 37
    Teng D, Chen Y, Lian L, Ha P, Tavtigian S, Wong A. Mutation analyses of 268 candidate genes in human tumor cell lines. Genomics 2001; 74: 35264.
  • 38
    Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 8226.
  • 39
    Leytus SP, Loeb KR, Hagen FS, Kurachi K, Davie EW. A novel trypsin-like serine protease (hepsin) with a putative transmembrane domain expressed by human liver and hepatoma cells. Biochemistry 1988; 27: 106774.
  • 40
    Teng D, Perry WR, Hogan J, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, Hu R, Jammulapati S, et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57: 417782.
  • 41
    Melino G, De Laurenzi V, Vousden K. p73: friend or foe in tumorigenesis. Nat Rev Cancer 2002; 2: 60515.
  • 42
    Nicholson S, Okby N, Khan M, Welsh J, McMenamin M, Travis W, Jett J, Tazelaar H, Trastek V, Pairolero P, Corn P, Herman J, et al. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 2001; 61: 563643.
  • 43
    Jin M, Piao Z, Kim N, Park C, Shin E, Park J, Jung H, Kim C, Kim H. p16 is a major inactivation target in hepatocellular carcinoma. Cancer Res 2001; 89: 608.
  • 44
    DeSouza A, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinoma with loss of heterozygosity. Nat Genet 1995; 11: 4479.
  • 45
    Yoshikawa H, Matsubara K, Qian G, Jackson P, Groopman J, Manning J, Harris C, Herman J. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 2935.
  • 46
    Woodford-Richens K, Rowan A, Gorman P, Halford S, Bicknell D, Wasan H, Roylance R, Bodmer W, Tomlinson I. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proc Natl Acad Sci USA 2001; 98: 971923.
  • 47
    Weintraub S. Inactivation of tumor suppressor genes in lung cancer. Am J Respir Cell Mol Biol 1996; 15: 1505.
  • 48
    Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, Mossner J, Berr F. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer 2002; 97: 4818.
  • 49
    Bianchi A, Hara T, Ramesh V, Gao J, Klein-Szanto A, Morin F, Menon A, Trofatter J, Gusella J, Seizinger BR, Kley N. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994; 6: 18592.
  • 50
    Arakawa H, Hayashi N, Nagase H, Ogawa M, Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet 1994; 3: 5658.
  • 51
    Marignani P, Kanai F, Carpenter C. LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest. J Biol Chem 2001; 276: 324158.
  • 52
    Avizienyte E, Roth S, Loukola A, Hemminki A, Lothe RA, Stenwig AE, Fossa SD, Salovaara R, Aaltonen LA. Somatic mutations in LKB1 are rare in specific colorectal and testicular tumors. Cancer Res 1998; 58: 208790.
  • 53
    Guldberg P, Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 1999; 18: 177780.
  • 54
    Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, Westerman AM, Entius MM, Goggins M, Yeo CJ, Kern SE. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Path 1999; 154: 183540.
  • 55
    Esteller M, Avizienyte E, Corn P, Lothe R, Baylin S, La A, Herman J. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 2000; 19: 1648.
  • 56
    Tiainen M, Ylikorkala A, Makela T. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci USA 1999; 96: 924851.
  • 57
    Langbein S, Szakacs O, Wilhelm M, Sukosd F, Weber S, Jauch A, Lopez Beltran A, Alken P, Kalble T, Kovacs G. Alteration of the LRP1B gene region is associated with high grade of urothelial cancer. Lab Invest 2002; 82: 63943.